Hepatitis D virus infection in Isfahan, central Iran: Prevalence and risk factors among chronic HBV infection cases by Ataei, Behrooz et al.
KOWSAR
Hepat Mon. 2011;11(4):269-272
Journal home page: www.HepatMon.ir
Hepatitis D virus infection in Isfahan, central Iran: Prevalence and risk fac-
tors among chronic HBV infection cases 
Behrooz  Ataei  1,  Mohammad  Reza  Yazdani  1,  Hamid  Kalantari  2,  Majid  Yaran  1,  Zary 
Nokhodian 1, Abbas Ali Javadi 1, Anahita Babak 3, Peyman Adibi 2 *
1 Isfahan Infectious Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Isfahan Liver Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran
3 Community and Preventive Medicine Specialist, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, 
Isfahan, IR Iran
ABSTRACT
Background: Hepatitis D virus (HDV) is dependent on hepatitis B virus (HBV) infection. 
Acute infection with HDV can occur simultaneously with acute HBV infection or be 
superimposed onto a chronic HBV infection. 
Objectives: This study aimed to identify cases of HDV and determine its prevalence in 
patients with chronic HBV infection for the first time study in Isfahan, central Iran.
Patients and Methods: In a cross-sectional study in 2009, 346 who had been diagnosed 
for at least 6 months with chronic HBV were enrolled consecutively. Anti-HDV was 
measured by ELISA in the serum of these patients. 
Results: The study included 245 males (70.8%) and 101 (29.2%) females with a mean age 
of 39 ± 12.4 years. Anti-HDV was present in 8 (3.5%) HBe antibody-positive patients (p = 
0.36) and in 2 (2.3%) HBe antigen-positive cases (p = 0.68). No association was found 
between hepatitis D and probable risk factors.
Conclusions: This study demonstrates that the prevalence of HDV infection is higher in 
patients who are positive for HBeAb compared those who are HBeAg-positive. There-
fore, most HDV antibody-positive cases in Isfahan are HBV/HDV superinfections but 
not coinfections.
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Background
Hepatitis B (HBV) is one of the most common public 
health  problems  worldwide,  especially  in  developing 
countries, causing 1 million deaths per year (1). According 
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to available estimates, 1.2% to 9.7% of the world’s popula-
tion and approximately 2.14% of the Iranian population 
have an HBV infection (2). Such patients not only are a 
source of infection but also are susceptible to late com-
plications of this virus, such as chronic active hepatitis, 
cirrhosis, and liver cancer (3).
Hepatitis D virus (HDV) is a defective RNA virus that de-
pends on the hepatitis B surface antigen (HBsAg) of hepa-
titis B virus for its replication, developing exclusively in 
patients with acute or chronic hepatitis B. Simultaneous Hepat Mon. 2011;11(4):269-272
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infection with HDV tends to accelerate the progression of 
chronic HBV infection to chronic active hepatitis, cirrho-
sis, and hepatocellular carcinoma and mediates fulmi-
nant hepatitis. In addition, the response of HDV patients 
to antiviral therapy and the required dosages of thera-
peutic regimens differ from those of chronic hepatitis B 
alone (4, 5).
Approximately 5% of patients with chronic hepatitis B 
infection worldwide are infected with hepatitis D virus. 
Its prevalence in Italy, eastern Europe, and western Asia is 
higher than in the rest of the world, reaching 83.3%, 8.3%, 
and 12.5% in Romania, Italy, and Russia, respectively (5-7).
HDV has a broad geographical distribution with two 
dominant patterns of transmission. In endemic regions, 
such as southern Italy, parts of Africa, and South Amer-
ica, it is transferred through close personal contact in 
the absence of clear skin contact, such as close personal 
relationships among members of a family. In contrast, 
in areas that have a low prevalence, such as western Eu-
rope and North America, HDV is seen more commonly 
in groups with frequent skin contact such as continual 
recipients of blood and blood products and intravenous 
drug users (8, 9). Sex and maternal-child transmission 
are other modes of transmission (1, 4).
The most frequent method of diagnosis of HDV infec-
tion is measurement of anti-HDV (IgM, IgG) in serum by 
ELISA. PCR can also be used to detect viral RNA in blood 
(10, 11).
Acute  HDV  infection  can  occur  simultaneously  with 
acute HBV infection or can be superimposed onto chron-
ic HBV infection. Fatal fulminant hepatitis occurs in 20% 
to 30% of coinfections of HDV and HBV in humans versus 
2% of patients with acute hepatitis B without HDV coin-
fection (1). More than 3% of the Iranian population is in-
fected with HBV, and few studies have been conducted to 
determine the prevalence of HDV in chronic HBV patients 
in Iran. No study has examined this topic in Isfahan, the 
second largest city in Iran.
Objectives
This study was designed and performed in 2009 to de-
tect anti-HDV in chronic HBV patients and related risk 
factors in this region. 
Patients and Methods
This cross-sectional study was performed from April to 
November 2009. We included patients with chronic hep-
atitis B virus infection who were in a carrier state (nor-
mal ALT, normal sonography, normal physical exam, and 
negative for HBeAg) or exhibited immune tolerance (nor-
mal ALT, normal sonography, normal physical exam, and 
HBeAg-positive) and under surveillance at the Infectious 
Diseases and Tropical Medicine Research Center, Isfahan 
University of Medical Sciences, with at least 6 months of 
diagnosis. In these patients, HBsAg was detected by in-
dividual, familial, or disease-related follow-up, and they 
were  tested  periodically  to  measure  viral  activity  and 
liver function.
Sampling was performed by nonprobability purposive 
technique.  Consecutive  patients  of  all  ages  and  both 
genders were included in the study, and patients with 
thalassemia and frequent recipients of blood and blood 
products were excluded. Persons who did not consent to 
participation in the study were not enrolled.
For  all  patients,  demographics  and  risk  factors  were 
recorded and 5-mL blood samples were collected. Total 
HDV antibody was detected by ELISA (Diapro, Italy). Re-
sults on HBsAb, HBeAg, HBeAb, and HBV DNA were ex-
tracted from the patients’ records. Laboratory results on 
other variables, such as age, sex, duration of hepatitis, 
methods of diagnosis, and risk factors of hepatitis, were 
recorded for each patient. Data were analyzed using SPSS, 
version 15, using descriptive statistical methods and chi-
square, Fisher’s exact, independent t, and logistic regres-
sion tests. P-values of less than 0.05 were considered sig-
nificant.
Variable Number Percentage
Intravenous drug users 20 5.8
Surgery 144 41.6
Blood transfusion 40 11.6
Transplantation 1 0.3
History of hepatitis in the family 186 53.8
Uterine curettage 12 11.9 a
Dialysis 13 3.8
Dental manipulation 292 84.4
Tattoo 54 15.6
Ear Piercing 91 26.3
Circumcision 243 99.2 b
High-risk sex 6 1.7
Phlebotomy 60 17.3
Table 1. Frequency of risk factors of hepatitis B virus infection in participants
a only in females 
b only in males 
Marker HDV antibody p-value
Positive [No. (%)] Negative [No. (%)]
HBe antigen
Positive
Negative
2 (2.3%)
8 (3.1%)
86 (97.7%)
248 (96.9%)
0.68
HBe antibody
Positive
Negative
8 (3.5%)
2 (1.7%)
221 (96.5%)
113 (98.3%)
0.36
HBs antibody
Positive
Negative
_
_
26 (100%)
16 (100%)
_
HBV DNA
Positive
Negative
1 (2.6%)
2 (11.1%)
38 (97.4%)
16 (88.9%)
0.23
Table 2. Frequency of hepatitis B markers relative to HDV antibodyHepat Mon. 2011;11(4):269-272
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Results
Overall, 346 cases, comprising 245 men (70.8%) and 101 
women (29.2%) with a mean age of 39 ± 12.4 years (40.4 
± 11.8 and 35.8 ± 13.2 years, respectively, p-value = 0.003), 
were studied. The median time from diagnosis of infec-
tion with hepatitis B virus was 3 years (range, 1 month to 
31 years). With regard to marital status, 54 cases (15.6%) 
were single, 290 cases (83.8%) were married, and 2 pa-
tients (0.6%) were widowed.
With regard to mode of diagnosis, the HBV was detect-
ed by disease-related follow up in 130 cases (37.6%), famil-
ial check-up in 105 cases (30.3%), by individual testing in 
30 cases (8.7%), after blood donation in 69 cases (19.9 %), 
during pregnancy in 10 patients (2.9%), and by congenital 
assay in 2 cases (0.6%).
The distribution of frequencies of risk factors for hepa-
titis B is shown in Table 1. Ten cases (2.9%) had antibodies 
against hepatitis D virus (6 males = 2.4% and 4 females = 
4%, p-value = 0.44). The status of HDV infection relative 
to hepatitis B is shown in Table 2. We observed that 3.5% 
of  HBeAb-positive  patients  and  2.3%  of  HBeAg-positive 
patients had HDV antibody; ie, the prevalence of HDV Ab 
was  higher  in  HBeAb-positive  patients  compared  with 
HBeAg-positive patients.
On analysis of demographic and risk factors by logistic 
regression, no statistically significant relationship was 
noted between hepatitis D and probable risk factors. We 
calculated odds ratios (ORs) with 95% confidence inter-
vals (CI) of various factors, presented in Table 3. Multivari-
ate logistic regression analysis was used to control for 
the confounding effects of other variables and estimate 
the adjusted odds ratios, shown in Table 3. 
Discussion
The prevalence of serum HDV antibody in our study 
group was 2.9%. In this study, a family history of hepati-
tis, phlebotomy, surgery, blood transfusions, and dental 
manipulations were the most frequent risk factors in pa-
tients with HDV antibody.
Based on studies in Mediterranean countries, including 
the Middle East, HDV infection is transmitted primarily 
through noncutaneous routes, especially close personal 
contact, such as that between family members (3). Based 
on the results of this study and other reports, HDV trans-
mission and spread can be prevented by avoidance of an 
infected  person  in  close  family  relationships,  and  the 
disease can be diagnosed earlier by screening high-risk 
individuals and their families.
In 1990, Rezvan et al. detected HDV antibodies in 2.5% of 
asymptomatic HsAg carriers in Tehran, the capital of Iran 
(12). Karimi et al. in 2000 reported a 1.3% prevalence of HDV 
in chronic carriers of hepatitis B in Tehran (13). Amini et 
al. reported prevalence (2.4%) of HDV infection in similar 
research population in 1993 in Hamadan, western Iran 
(14). In 2000 in Babol, northern Iran, Hassanjani-Roshan 
and Taheri observed HDV positivity in 2% of HBV carriers 
(3). Roshandel and colleagues reported a 5.8% prevalence 
of HDV in Golestan, northern Iran, in 2008 (15). In Tabriz, 
northwestern Iran, in 2002,,Torabi and colleagues noted 
a prevalence of HDV antibody of 0.6% in HBsAg-positive 
individuals  (16).  Alavian  et  al.  reported  5.7%  HDV  sero-
positivity among HBV-infected subjects in Iran (17). These 
studies  demonstrate  that  the  prevalence  of  HBV/HDV 
coinfection and superinfection has increased in the past 
decade in Iran, during which the prevalence of acute and 
chronic hepatitis D has decreased worldwide (18).
The prevalence of HDV among HBsAg-positive individu-
als has been reported to be 1.5% in Yugoslavia (19), 1.6% in 
Spain (10), 2.2% in Taiwan (20), 4% in Mexico (21), 16.6% in 
Pakistan (22), 24.4% in Bangladesh (1), 12.5% in Russia (7), 
83.3% in Romania (5), 23.6% in Japan (23), and 8.3% in Italy 
(6). These studies suggest that the prevalence of HDV dif-
fers in various parts of the world and is higher in east-
Variable OR (95% CI)  adjusted OR (95% CI)
Age 0.97 (0.92-1.01)  0.96 (0.91-1.02)
Sex a 0.6 (0.16-2.19) 1.97 (0.42-9.23)
Marital status b 31.11 (1.79-537.93) e 1.12 (0.11-11) 
Duration of HBV infection 1.02 (0.84-1.24) 1.03 (0.8-1.32)
History of surgery c 0.94 (0.26-3.41) 1.54 (0.36-6.6)
History of blood transfusion c 0.89 (0.11-7.24) 1.09 (0.12-10)
History of hepatitis in the family c 1.31 (0.36-4.74) 0.82 (0.21-3.14)
History of dental manipulation c 073 (0.15-3.57) 1.47 (0.29-7.5)
History of Phlebotomy  1.19 (0.24-5.74) 0.86 (0.15-4.75)
HBe antigen d 0.72 (0.15-3.46) 0.44 (0.02-8.04)
HBe antibody d 2.04 (0.42-9.79) 0.32 (0.02-5. 85)
a female = 0 male = 1 (Reference category)
b single and widowed = 0, married = 1 (Reference category)
c has not had = 0, has had = 1 (Reference category) 
d negative = 0, positive = 1 (Reference category)
e statistically significant
Table 3. Odds ratios of risk factors of hepatitis D virus infectionHepat Mon. 2011;11(4):269-272
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ern Europe and western Asia. Our findings are consistent 
with the results of Hassanjani-Roshan, in which the rate 
of HDV infection in northern Iran was not significantly 
different between various age groups (3). Moreover, this 
prevalence  was  slightly,  but  insignificantly,  higher  in 
women.
The  prevalence  of  HDV  antibody  in  HbeAg-positive 
patients  was  higher  than  in  HBeAb-positive  cases,  but 
in our study, the prevalence of HDV antibody in HBeAb-
positive  patients  was  higher  compared  with  HBeAg-
positive persons. In Celen and colleagues, a significant 
relationship was reported in 2005 in Turkey between the 
duration of positivity of HBsAg and HDV antibody, but a 
significant relationship did not exist between HBeAg or 
antibody and HDV antibody (24). We did not observe an 
association between the duration of HBV and HDV infec-
tion. Local data have shown that the progression of liver 
damage in cases of HBV infection are not low, suggesting 
that prognostic indicators, including coinfections and 
superinfections, must be determined (25). 
In conclusion, researchers should be aware of the risk 
of coinfection and superinfection of HBV and HDV in this 
region. The prevalence of HDV in high-risk individuals in 
Iran has only been reported by Karimi and colleagues, 
who  noted  HDV  antibody  in  25.2%  of  dialysis  patients 
in  Tehran  (13).  Therefore,  it  is  necessary  to  assess  the 
frequency of HDV in high-risk individuals, including in-
travenous drug users and continual recipients of blood 
and blood products, such as patients with thalassemia, 
hemophilia, and coagulation factor deficiencies, in Isfa-
han and other regions of Iran. In addition, studies are 
necessary to identify transmission routes of HDV in Isfa-
han and other regions of Iran to design programs for the 
prevention of HDV infection in the community.
Because liver lesions are more severe in patients with 
HBV/HDV coinfections and because the frequency of HDV 
in patients with liver lesions is unknown in Iran, it is nec-
essary to determine the prevalence of HDV in patients 
with chronic active hepatitis, cirrhosis, liver cancer, and 
resistant chronic hepatitis B and in asymptomatic chron-
ic carriers of hepatitis B in Isfahan and other parts of Iran 
separately. 
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